Product NDC: | 55390-109 |
Proprietary Name: | Clindamycin |
Non Proprietary Name: | Clindamycin phosphate |
Active Ingredient(s): | 150 mg/mL & nbsp; Clindamycin phosphate |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 55390-109 |
Labeler Name: | Bedford Laboratories |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | ANDA065206 |
Marketing Category: | ANDA |
Start Marketing Date: | 20050404 |
Package NDC: | 55390-109-01 |
Package Description: | 1 VIAL in 1 BOX, UNIT-DOSE (55390-109-01) > 60 mL in 1 VIAL |
NDC Code | 55390-109-01 |
Proprietary Name | Clindamycin |
Package Description | 1 VIAL in 1 BOX, UNIT-DOSE (55390-109-01) > 60 mL in 1 VIAL |
Product NDC | 55390-109 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | Clindamycin phosphate |
Dosage Form Name | INJECTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 20050404 |
Marketing Category Name | ANDA |
Labeler Name | Bedford Laboratories |
Substance Name | CLINDAMYCIN PHOSPHATE |
Strength Number | 150 |
Strength Unit | mg/mL |
Pharmaceutical Classes | Decreased Sebaceous Gland Activity [PE],Lincosamide Antibacterial [EPC],Lincosamides [Chemical/Ingredient] |